Literature DB >> 34001771

Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019.

Saeid Safiri1,2, Hojjat Pourfathi3, Arielle Eagan4,5, Mohammad Ali Mansournia6, Mohammad Taghi Khodayari7, Mark J M Sullman8,9, Jay Kaufman10, Gary Collins11,12, Haijiang Dai13, Nicola Luigi Bragazzi13, Ali-Asghar Kolahi14.   

Abstract

ABSTRACT: Data from the Global Burden of Disease Study 2019 were used to report the burden of migraine in 204 countries and territories during the period 1990 to 2019, through a systematic analysis of point prevalence, annual incidence, and years lived with disability (YLD). In 2019, the global age-standardised point prevalence and annual incidence rate of migraine were 14,107.3 (95% Uncertainty Interval [UI] 12,270.3-16,239) and 1142.5 (95% UI 995.9-1289.4) per 100,000, an increase of 1.7% (95% UI 0.7%-2.8%) and 2.1% (95% UI 1.1%-2.8%) since 1990, respectively. Moreover, the global age-standardised YLD rate in 2019 was 525.5 (95% UI 78.8-1194), an increase of 1.5% (95% UI -4.4% to 3.3%) since 1990. The global point prevalence of migraine in 2019 was higher in females and increased by age up to the 40 to 44 age group, then decreased with increased age. Belgium (22,400.6 [95% UI: 19,305.2-26,215.8]), Italy (20,337.7 [95% UI: 17,724.7-23,405.8]), and Germany (19,436.4 [95% UI: 16,806.2-22,810.3]) had the 3 highest age-standardised point prevalence rates for migraine in 2019. In conclusion, there were large intercountry differences in the burden of migraine, and this burden increased significantly across the measurement period. These findings suggest that migraine care needs to be included within the health system to increase population awareness regarding the probable risk factors and treatment strategies especially among young adults and middle-aged women, as well as to increase the data on migraines.
Copyright © 2021 International Association for the Study of Pain.

Entities:  

Mesh:

Year:  2022        PMID: 34001771     DOI: 10.1097/j.pain.0000000000002275

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  9 in total

1.  Association between patent foramen ovale and migraine without aura: a community-based cross-sectional study in China.

Authors:  Yusha Tang; Anjiao Peng; Bo Peng; Shixu He; Xia Zhao; Yuanfeng Zhu; Wanlin Lai; Tingting Song; Lei Chen
Journal:  BMJ Open       Date:  2022-03-31       Impact factor: 2.692

Review 2.  The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine.

Authors:  Simona Guerzoni; Carlo Baraldi; Luca Pani
Journal:  Neurol Sci       Date:  2022-06-10       Impact factor: 3.830

3.  TRPM8 contributes to sex dimorphism by promoting recovery of normal sensitivity in a mouse model of chronic migraine.

Authors:  David Alarcón-Alarcón; David Cabañero; Jorge de Andrés-López; Magdalena Nikolaeva-Koleva; Simona Giorgi; Gregorio Fernández-Ballester; Asia Fernández-Carvajal; Antonio Ferrer-Montiel
Journal:  Nat Commun       Date:  2022-10-22       Impact factor: 17.694

4.  Circadian Variation of Migraine Attack Onset Affects fMRI Brain Response to Fearful Faces.

Authors:  Daniel Baksa; Edina Szabo; Natalia Kocsel; Attila Galambos; Andrea Edit Edes; Dorottya Pap; Terezia Zsombok; Mate Magyar; Kinga Gecse; Dora Dobos; Lajos Rudolf Kozak; Gyorgy Bagdy; Gyongyi Kokonyei; Gabriella Juhasz
Journal:  Front Hum Neurosci       Date:  2022-03-09       Impact factor: 3.169

Review 5.  Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities.

Authors:  Parastoo Amiri; Somayeh Kazeminasab; Seyed Aria Nejadghaderi; Reza Mohammadinasab; Hojjat Pourfathi; Mostafa Araj-Khodaei; Mark J M Sullman; Ali-Asghar Kolahi; Saeid Safiri
Journal:  Front Neurol       Date:  2022-02-23       Impact factor: 4.003

6.  Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study.

Authors:  Oralee J Varnado; Janna Manjelievskaia; Wenyu Ye; Allison Perry; Kory Schuh; Richard Wenzel
Journal:  Patient Prefer Adherence       Date:  2022-03-29       Impact factor: 2.711

7.  The increased iron deposition of the gray matter over the whole brain in chronic migraine: An exploratory quantitative susceptibility mapping study.

Authors:  Zhiye Chen; He Zhao; Xiaoyan Chen; Mengqi Liu; Xin Li; Lin Ma; Shengyuan Yu
Journal:  Mol Pain       Date:  2022 Jan-Dec       Impact factor: 3.395

Review 8.  Applying a biopsychosocial model to migraine: rationale and clinical implications.

Authors:  Chiara Rosignoli; Raffaele Ornello; Agnese Onofri; Valeria Caponnetto; Licia Grazzi; Alberto Raggi; Matilde Leonardi; Simona Sacco
Journal:  J Headache Pain       Date:  2022-08-11       Impact factor: 8.588

Review 9.  The Patent Foramen Ovale and Migraine: Associated Mechanisms and Perspectives from MRI Evidence.

Authors:  Wenfei Cao; Yinbo Shen; Jiaqi Zhong; Zhenhong Chen; Nizhuan Wang; Jiajun Yang
Journal:  Brain Sci       Date:  2022-07-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.